Medical treatments for endometriosis-associated pelvic pain

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Zito, Gabriella ^a   Luppi, Stefania ^b   Giolo, Elena ^b   Martinelli, Monica ^b   Venturin, Irene ^a   Di Lorenzo, Giovanni ^a   Ricci, Giuseppe ^a,b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; ASOPRISNIL; BUSERELIN ACETATE; CITRATE CALCIUM; CYPROTERONE ACETATE; DANAZOL; DIENOGEST; ETONOGESTREL; GESTAGEN; GESTRINONE; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; LETROZOLE; LEUPRORELIN; LEVONORGESTREL; LOW DOSE ORAL CONTRACEPTIVE; MEDROXYPROGESTERONE ACETATE; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROGESTERONE RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIPTORELIN; UNINDEXED DRUG; GONADORELIN; HORMONE ANTAGONIST;

AMENORRHEA; ANALGESIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL PRACTICE; DECIDUALIZATION; DRUG EFFICACY; DRUG MECHANISM; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; NONHUMAN; OUTCOME ASSESSMENT; OVARY FOLLICLE; PAIN INTENSITY; PELVIS PAIN SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; COMPLICATION; FEMALE; PATHOLOGY; PELVIC PAIN;

ANIMALIA;

ENDOMETRIOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HISTONE DEACETYLASE INHIBITORS; HORMONE ANTAGONISTS; HUMANS; PAIN MANAGEMENT; PELVIC PAIN; PROGESTINS;

EID: 84925414551     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/191967     Document Type: Article

References (134)

1. L. C. Giudice and L. C. Kao, "Endometriosis", The Lancet, vol. 364, no. 9447, pp. 1789-1799, 2004.
2. S. Guo and Y. Wang, "The prevalence of endometriosis in women with chronic pelvic pain", Gynecologic and Obstetric Investigation, vol. 62, no. 3, pp. 121-130, 2006.
3. S. Simoens, G. Dunselman, C. Dirksen et al., "The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres", Human Reproduction, vol. 27, no. 5, pp. 1292-1299, 2012.
4. U. Menakaya, F. Infante, and G. Condous, "Consensus on current management of endometriosis", Human Reproduction, vol. 28, pp. 3162-3163, 2013.
5. G. A. Dunselman, N. Vermeulen, C. Becker et al., "ESHRE guideline: management of women with endometriosis", Human Reproduction, vol. 29, pp. 400-412, 2014.
6. R. W. Kistner, "Treatment of endometriosis by inducing pseudo-pregnancy with ovarian hormones", Fertility and Sterility, vol. 10, pp. 539-554, 1959.
7. H. Sullivan, H. Furniss, J. Spona, and M. Elstein, "Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity", Fertility and Sterility, vol. 72, no. 1, pp. 115-120, 1999.
8. T. Harada, M. Momoeda, Y. Taketani, H. Hoshiai, and N. Terakawa, "Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, doubleblind, randomized trial", Fertility and Sterility, vol. 90, no. 5, pp. 1583-1588, 2008.
9. P. Vercellini, B. Eskenazi, D. Consonni et al., "Oral contraceptives and risk of endometriosis: a systematic review and metaanalysis", Human Reproduction Update, vol. 17, no. 2, Article ID dmq042, pp. 159-170, 2011.
10. P. Vercellini, O. de Giorgi, P. Mosconi, G. Stellato, S. Vicentini, and P. G. Crosignani, "Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis", Fertility and Sterility, vol. 77, no. 1, pp. 52-61, 2002.
11. R. Seracchioli, M. Mabrouk, L. Manuzzi et al., "Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis", Human Reproduction, vol. 24, no. 11, pp. 2729-2735, 2009.
12. C. Seibert, E. Barbouche, J. Fagan, E. Myint, T. Wetterneck, and M. Wittemyer, "Prescribing oral contraceptives for women older than 35 years of age", Annals of Internal Medicine, vol. 138, no. 1, pp. 54-64, 2003.
13. S. R. Soares, A. Martínez-Varea, J. J. Hidalgo-Mora, and A. Pellicer, "Pharmacologic therapies in endometriosis: a systematic review", Fertility and Sterility, vol. 98, no. 3, pp. 529-555, 2012.
14. J. S. McLaren, E. Morris, and J. Rymer, "Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update", Menopause International, vol. 18, no. 2, pp. 68-72, 2012.
15. A. Kauppila, P. Vierikko, and H. Isotalo, "Cytosol estrogen and progestin receptor concentrations and 17β-hydroxysteroid dehydrogenase activities in the endometrium and endometriotic tissue. Effects of hormonal treatment", Acta Obstetricia et Gynecologica Scandinavica, vol. 63, no. 123, pp. 45-49, 1984.
16. P. Vierikko, A. Kauppila, L. Ronnberg, and R. Vihko, "Steroidal regulation of endometriosis tissue: lack of induction of 17β-hydroxysteroid dehydrogenase activity by progesterone, medroxyprogesterone acetate, or danazol", Fertility and Sterility, vol. 43, no. 2, pp. 218-224, 1985.
17. J. Brown, S. Kives, and M. Akhtar, "Progestagens and antiprogestagens for pain associated with endometriosis", Cochrane Database of Systematic Reviews, vol. 3, p. CD002122, 2012.
18. L. Fedele, S. Bianchi, G. Zanconato, A. Portuese, and R. Raffaelli, "Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis", Fertility and Sterility, vol. 75, no. 3, pp. 485-488, 2001.
19. Y. Bayoglu Tekin, B. Dilbaz, S. K. Altinbas, and S. Dilbaz, "Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue", Fertility and Sterility, vol. 95, no. 2, pp. 492-496, 2011.
20. A. M. Abou-Setta, B. Houston, H. G. Al-Inany, and C. Farquhar, "Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery", Cochrane Database of Systematic Reviews, vol. 1, Article ID CD005072, 2013.
21. C. A. Petta, R. A. Ferriani, M. S. Abrao et al., "Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis", Human Reproduction, vol. 20, no. 7, pp. 1993-1998, 2005.
22. A. Y. Wong, L. C. Tang, and R. K. Chin, "Levonorgestrelreleasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial", Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 20, pp. 273-279, 2010.
23. K. Walch, G. Unfried, J. Huber et al., "Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis-a pilot study", Contraception, vol. 79, no. 1, pp. 29-34, 2009.
24. F. Z. Stanczyk and S. Roy, "Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids", Contraception, vol. 42, no. 1, pp. 67-96, 1990.
25. O. Muneyyirci-Delale and M. Karacan, "Effect of norethindrone acetate in the treatment of symptomatic endometriosis", International Journal of Fertility and Women's Medicine, vol. 43, no. 1, pp. 24-27, 1998.
26. P. Vercellini, L. Fedele, G. Pietropaolo, G. Frontino, E. Somigliana, and P. G. Crosignani, "Progestogens for endometriosis: forward to the past", Human Reproduction Update, vol. 9, no. 4, pp. 387-396, 2003.
27. P. Vercellini, G. Pietropaolo, O. De Giorgi, R. Pasin, A. Chiodini, and P. G. Crosignani, "Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate", Fertility and Sterility, vol. 84, no. 5, pp. 1375-1387, 2005.
28. S. Ferrero, G. Camerini, R. Seracchioli, N. Ragni, P. L. Venturini, and V. Remorgida, "Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis", Human Reproduction, vol. 24, no. 12, pp. 3033-3041, 2009.
29. S. Ferrero, G. Camerini, N. Ragni, P. L. Venturini, E. Biscaldi, and V. Remorgida, "Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study", Human Reproduction, vol. 25, no. 1, pp. 94-100, 2010.
30. T. Harada and F. Taniguchi, "Dienogest: a new therapeutic agent for the treatment of endometriosis", Women's Health, vol. 6, no. 1, pp. 27-35, 2010.
31. A. E. Schindler, "Dienogest in long-term treatment of endometriosis", International Journal of Women's Health, vol. 3, no. 1, pp. 175-184, 2011.
32. P. L. McCormack, "Dienogest: a review of its use in the treatment of endometriosis", Drugs, vol. 70, no. 16, pp. 2073-2088, 2010.
33. G. Köhler, T. A. Faustmann, C. Gerlinger, C. Seitz, and A. O. Mueck, "A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis", International Journal of Gynecology and Obstetrics, vol. 108, no. 1, pp. 21-25, 2010.
34. T. Strowitzki, T. Faustmann, C. Gerlinger, and C. Seitz, "Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study", European Journal of Obstetrics Gynecology & Reproductive Biology, vol. 151, no. 2, pp. 193-198, 2010.
35. F. Petraglia, D. Hornung, C. Seitz et al., "Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment", Archives of Gynecology and Obstetrics, vol. 285, no. 1, pp. 167-173, 2012.
36. T. Strowitzki, J. Marr, C. Gerlinger, T. Faustmann, and C. Seitz, "Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial", Human Reproduction, vol. 25, no. 3, pp. 633-641, 2010.
37. M. Cosson, D. Querleu, J. Donnez et al., "Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study", Fertility and Sterility, vol. 77, no. 4, pp. 684-692, 2002.
38. T. Harada, M. Momoeda, Y. Taketani et al., "Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis-a randomized, double-blind, multicenter, controlled trial", Fertility and Sterility, vol. 91, no. 3, pp. 675-681, 2009.
39. R. B. Greenblatt, W. P. Dmowski, V. B. Mahesh, and H. F. Scholer, "Clinical studies with an antigonadotropin-Danazol.", Fertility and Sterility, vol. 22, no. 2, pp. 102-112, 1971.
40. P. Crosignani, D. Olive, A. Bergqvist, and A. Luciano, "Advances in the management of endometriosis: an update for clinicians", Human Reproduction Update, vol. 12, no. 2, pp. 179-189, 2006.
41. P. Vercellini, E. Somigliana, P. Viganò, A. Abbiati, G. Barbara, and P. G. Crosignani, "Endometriosis: current therapies and new pharmacological developments", Drugs, vol. 69, no. 6, pp. 649-675, 2009.
42. M. Igarashi, M. Iizuka, Y. Abe, and Y. Ibuki, "Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis", Human Reproduction, vol. 13, no. 7, pp. 1952-1956, 1998.
43. C. M. Cottreau, R. B. Ness, F. Modugno, G. O. Allen, and M. T. Goodman, "Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer", Clinical Cancer Research, vol. 9, no. 14, pp. 5142-5144, 2003.
44. T. Tamaya, J. Fujimoto, Y. Watanabe, K. Arahori, and H. Okada, "Gestrinone (R2323) binding to steroid receptors in human uterine endometrial cytosol", Acta Obstetricia et Gynecologica Scandinavica, vol. 65, no. 5, pp. 439-441, 1986.
45. L. Fedele, S. Bianchi, T. Viezzoli, L. Arcaini, and G. B. Candiani, "Gestrinone versus danazol in the treatment of endometriosis", Fertility and Sterility, vol. 51, no. 5, pp. 781-785, 1989.
46. A. Prentice, "Regular review: endometriosis", The British Medical Journal, vol. 323, no. 7304, pp. 93-95, 2001.
47. R. W. Shaw, "GnRH analogues in the treatment of endometriosis-rationale and efficacy", in Modern Approaches to Endometriosis, E. J. Thomas and J. A. Rock, Eds., pp. 257-274, Kluwer Academic Publishers, London, UK, 1990.
48. M. D. Hornstein, A. A. Yuzpe, K. A. Burry, L. R. Heinrichs, V. L. Buttram Jr., and E. S. Orwoll, "Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain", Fertility and Sterility, vol. 63, no. 5, pp. 955-962, 1995.
49. E. S. Surrey and M. D. Hornstein, "Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up", Obstetrics & Gynecology, vol. 99, no. 5, pp. 709-719, 2002.
50. E. S. Surrey, "Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?" Current Opinion in Obstetrics and Gynecology, vol. 22, no. 4, pp. 283-288, 2010.
51. W. Küpker, R. E. Felberbaum, M. Krapp, T. Schill, E. Malik, and K. Diedrich, "Use of GnRH antagonists in the treatment of endometriosis", Reproductive Biomedicine Online, vol. 5, no. 1, pp. 12-16, 2002.
52. D. Finas, D. Hornung, K. Diedrich, and A. Schultze-Mosgau, "Cetrorelix in the treatment of female infertility and endometriosis", Expert Opinion on Pharmacotherapy, vol. 7, no. 15, pp. 2155-2168, 2006.
53. M. P. Diamond, B. Carr, W. P. Dmowski et al., "Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study", Reproductive Sciences, vol. 21, no. 3, pp. 363-371, 2014.
54. C. Allen, S. Hopewell, A. Prentice, and D. Gregory, "Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis", Cochrane Database of Systematic Reviews, vol. 2, Article ID CD004753, 2009.
55. E. C. Hayes and J. A. Rock, "COX-2 inhibitors and their role in gynecology", Obstetrical and Gynecological Survey, vol. 57, no. 11, pp. 768-780, 2002.
56. E. Dogan, U. Saygili, C. Posaci et al., "Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib", Fertility and Sterility, vol. 82, supplement 3, pp. 1115-1120, 2004.
57. L. Cobellis, S. Razzi, S. De Simone et al., "The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis", European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 116, no. 1, pp. 100-102, 2004.
58. G. F. Meresman, M. Bilotas, V. Abello, R. Buquet, M. Tesone, and C. Sueldo, "Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis", Fertility and Sterility, vol. 84, no. 2, pp. 459-463, 2005.
59. I. Velasco, J. Rueda, and P. Acién, "Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis", Molecular Human Reproduction, vol. 12, no. 6, pp. 377-381, 2006.
60. S. E. Bulun, S. Yang, Z. Fang, B. Gurates, M. Tamura, and S. Sebastian, "Estrogen production and metabolism in endometriosis", Annals of the New York Academy of Sciences, vol. 955, pp. 75-85, 2002.
61. M. E. Pavone and S. E. Bulun, "Aromatase inhibitors for the treatment of endometriosis", Fertility and Sterility, vol. 98, no. 6, pp. 1370-1379, 2012.
62. L. L. Amsterdam, W. Gentry, S. Jobanputra, M. Wolf, S. D. Rubin, and S. E. Bulun, "Anastrazole and oral contraceptives: a novel treatment for endometriosis", Fertility and Sterility, vol. 84, no. 2, pp. 300-304, 2005.
63. R. K. Ailawadi, S. Jobanputra, M. Kataria, B. Gurates, and S. E. Bulun, "Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study", Fertility and Sterility, vol. 81, no. 2, pp. 290-296, 2004.
64. V. Remorgida, L. H. Abbamonte, N. Ragni, E. Fulcheri, and S. Ferrero, "Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis", Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 47, no. 3, pp. 222-225, 2007.
65. V. Remorgida, H. L. Abbamonte, N. Ragni, E. Fulcheri, and S. Ferrero, "Letrozole and norethisterone acetate in rectovaginal endometriosis", Fertility and Sterility, vol. 88, no. 3, pp. 724-726, 2007.
66. F. Abushahin, K. N. Goldman, E. Barbieri, M. Milad, A. Rademaker, and S. E. Bulun, "Aromatase inhibition for refractory endometriosis-related chronic pelvic pain", Fertility and Sterility, vol. 96, no. 4, pp. 939-942, 2011
67. Erratum in: Fertility and Sterility, vol. 97, p. 1017, 2012.
68. J. Buelke-Sam, H. U. Bryant, and P. C. Francis, "The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing", Reproductive Toxicology, vol. 12, no. 3, pp. 217-221, 1998.
69. D. K. Swisher, R. M. Tague, and D. E. Seyler, "Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats", Drug Development Research, vol. 36, no. 1, pp. 43-45, 1995.
70. P. Fanning, T. J. Kuehl, R. Lee et al., "Video mapping to assess efficacy of an antiestrogen (raloxifene) on spontaneous endometriosis in the rhesus monkey, Macaca mulatta", in Bunkley Day Proceedings, T. J. Kuehl, Ed., pp. 51-61, Texas A&M University Health Science Center, Temple, Tex, USA, 1996.
71. P. Stratton, N. Sinaii, J. Segars et al., "Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial", Obstetrics and Gynecology, vol. 111, no. 1, pp. 88-96, 2008.
72. D. I. Lebovic, M. D. Mueller, and R. N. Taylor, "Immunobiology of endometriosis", Fertility and Sterility, vol. 75, no. 1, pp. 1-10, 2001.
73. H. N. Ho, M. Y. Wu, and Y. S. Yang, "Peritoneal cell immunity and endometriosis", The American Journal of Reproductive Immunology, vol. 38, pp. 400-412, 1997.
74. W. Küpker, A. Schultze-Mosgau, and K. Diedrich, "Paracrine changes in the peritoneal environment of women with endometriosis", Human Reproduction Update, vol. 4, no. 5, pp. 719-723, 1998.
75. E. Somigliana, P. Viganò, G. Rossi, S. Carinelli, M. Vignali, and P. Panina-Bordignon, "Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis", Human Reproduction, vol. 14, no. 12, pp. 2944-2950, 1999.
76. P. Acién, F. J. Quereda, M. Gómez-Torres, R. Bermejo, and M. Gutierrez, "GnRH analogues, transvaginal ultrasound-guided drainage and intracystic injection of recombinant interleukin-2 in the treatment of endometriosis", Gynecologic and Obstetric Investigation, vol. 55, no. 2, pp. 96-104, 2003.
77. P. Acién, G. Pérez-Albert, F. J. Quereda, M. Sánchez-Ferrer, A. García-Almela, and I. Velasco, "Treatment of endometriosis with transvaginal ultrasound-guided drainage under GnRH analogues and recombinant interleukin-2 left in the cysts", Gynecologic and Obstetric Investigation, vol. 60, no. 4, pp. 224-231, 2005.
78. J. M. R. Ingelmo, F. Quereda, and P. Acién, "Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-α-2b in a murine model", Fertility and Sterility, vol. 71, no. 5, pp. 907-911, 1999.
79. J. A. Keenan, P. J. Massey, T. T. Chen, M. R. Caudle, and A. Bukovsky, "Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole", Fertility and Sterility, vol. 72, no. 1, pp. 135-141, 1999.
80. P. Acién, F. Quereda, A. Campos, M. J. Gomez-Torres, I. Velasco, and M. Gutierrez, "Use of intraperitoneal interferon α-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial", Fertility and Sterility, vol. 78, no. 4, pp. 705-711, 2002.
81. C. L. D'Hellencourt, L. Diaw, P. Cornillet, and M. Guenounou, "Differential regulation of TNFα, IL-1β, IL-6, IL-8, TNFβ, and IL-10 by pentoxifylline", International Journal of Immunopharmacology, vol. 18, no. 12, pp. 739-748, 1996.
82. D. P. Braun, J. Ding, and W. P. Dmowski, "Peritoneal fluidmediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-α in women with endometriosis", Fertility and Sterility, vol. 78, no. 4, pp. 727-732, 2002.
83. M. Sillem, S. Prifti, A. Koch, M. Neher, J. Jauckus, and B. Runnebaum, "Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis", European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 95, no. 2, pp. 167-174, 2001.
84. N. F. Vlahos, O. Gregoriou, A. Deliveliotou et al., "Effect of pentoxifylline on vascular endothelial growth factor C and flk-1 expression on endometrial implants in the rat endometriosis model", Fertility and Sterility, vol. 93, no. 4, pp. 1316-1323, 2010.
85. A. Steinleitner, H. Lambert, M. Suarez, N. Serpa, and S. Roy, "Immunomodulation in the treatment of endometriosisassociated subfertility: use of pentoxifylline to reverse the inhibition of fertilization by surgically induced endometriosis in a rodent model", Fertility and Sterility, vol. 56, no. 5, pp. 975-979, 1991.
86. H. Kamencic and J. A. Thiel, "Pentoxifylline after conservative surgery for endometriosis: a randomized, controlled trial", Journal of Minimally Invasive Gynecology, vol. 15, no. 1, pp. 62-66, 2008.
87. M. Creus, F. Fábregues, F. Carmona, M. del Pino, D. Manau, and J. Balasch, "Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial", Human Reproduction, vol. 23, no. 8, pp. 1910-1916, 2008.
88. J. Balasch, M. Creus, F. Fàbregues et al., "Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial", Human Reproduction, vol. 12, no. 9, pp. 2046-2050, 1997.
89. S. Alborzi, S. Ghotbi, M. E. Parsanezhad, S. Dehbashi, and M. Alborzi, "Pentoxifylline therapy after laparoscopic surgery for different stages of endometriosis: a prospective, double-blind, randomized, placebo-controlled study", Journal of Minimally Invasive Gynecology, vol. 14, no. 1, pp. 54-58, 2007.
90. D. Lu, H. Song, Y. Li, J. Clarke, and G. Shi, "Pentoxifylline for endometriosis", Cochrane Database of Systematic Reviews, vol. 1, Article ID CD007677, 2012.
91. M. D'Antonio, F. Martelli, S. Peano, R. Papoian, and F. Borrelli, "Ability of recombinant human TNF binding protein-1 (rhTBP-1) to inhibit the development of experimentally-induced endometriosis in rats", Journal of Reproductive Immunology, vol. 48, no. 2, pp. 81-98, 2000.
92. R. Grümmer, "Animal models in endometriosis research", Human Reproduction Update, vol. 12, no. 5, pp. 641-649, 2006.
93. B. F. Barrier, G. W. Bates, M. M. Leland, D. A. Leach, R. D. Robinson, and A. M. Propst, "Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons", Fertility and Sterility, vol. 81, supplement 1, pp. 775-779, 2004.
94. T. M. D'Hooghe, N. P. Nugent, S. Cuneo et al., "Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placeboand drug-controlled study", Biology of Reproduction, vol. 74, no. 1, pp. 131-136, 2006.
95. H. Falconer, J. M. Mwenda, D. C. Chai et al., "Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon", Human Reproduction, vol. 21, no. 7, pp. 1856-1862, 2006.
96. P. R. Koninckx, M. Craessaerts, D. Timmerman, F. Cornillie, and S. Kennedy, "Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial", Human Reproduction, vol. 23, no. 9, pp. 2017-2023, 2008.
97. D. Lu, H. Song, and G. Shi, "Anti-TNF-α treatment for pelvic pain associated with endometriosis.", The Cochrane database of systematic reviews, vol. 3, Article ID CD008088, 2013.
98. T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori, "Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials", Journal of the American Medical Association, vol. 295, no. 19, pp. 2275-2285, 2006.
99. T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori, "Erratum in "Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials"", JAMA, vol. 295, no. 21, p. 2482, 2006.
100. P. Froment, F. Gizard, D. Defever, B. Staels, J. Dupont, and P. Monget, "Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition", Journal of Endocrinology, vol. 189, no. 2, pp. 199-209, 2006.
101. G. L. Rubin, Y. Zhao, A. M. Kalus, and E. R. Simpson, "Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy", Cancer Research, vol. 60, no. 6, pp. 1604-1608, 2000.
102. D. I. Lebovic, S. K. Kavoussi, J. Lee, S. K. Banu, and J. A. Arosh, "PPARγ activation inhibits growth and survival of human endometriotic cells by suppressing estrogen biosynthesis and PGE2 signaling", Endocrinology, vol. 154, no. 12, pp. 4803-4813, 2013.
103. Y. Ohama, T. Harada, T. Iwabe, F. Taniguchi, Y. Takenaka, and N. Terakawa, "Peroxisome proliferator-activated receptor-γ ligand reduced tumor necrosis factor-α-induced interleukin-8 production and growth in endometriotic stromal cells", Fertility and Sterility, vol. 89, no. 2, pp. 311-317, 2008.
104. Y. Wu and S. Guo, "Peroxisome proliferator-activated receptorgamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells", Fertility and Sterility, vol. 91, no. 5, pp. 2142-2147, 2009.
105. C. Olivares, A. Ricci, M. Bilotas, R. I. Barañao, and G. Meresman, "The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis", Fertility and Sterility, vol. 96, no. 2, pp. 428-433, 2011.
106. H. Aytan, A. C. Caliskan, F. Demirturk, P. Aytan, and D. R. Koseoglu, "Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model", Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 47, no. 4, pp. 321-325, 2007.
107. D. I. Lebovic, J. M. Mwenda, D. C. Chai, A. Santi, X. Xu, and T. D'Hooghe, "Peroxisome proliferator-activated receptor-γ receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebocontrolled study", Endocrinology, vol. 151, no. 4, pp. 1846-1852, 2010.
108. J. Donnez, P. Smoes, S. Gillerot, F. Casanas-Roux, and M. Nisolle, "Vascular endothelial growth factor (VEGF) in endometriosis", Human Reproduction, vol. 13, no. 6, pp. 1686-1690, 1998.
109. J. McLaren, "Vascular endothelial growth factor and endometriotic angiogenesis", Human Reproduction Update, vol. 6, no. 1, pp. 45-55, 2000.
110. J. McLaren, A. Prentice, D. S. Charnock-Jones, and S. K. Smith, "Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis", Human Reproduction, vol. 11, no. 1, pp. 220-223, 1996.
111. L. E. Benjamin, I. Hemo, and E. Keshet, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF", Development, vol. 125, no. 9, pp. 1591-1598, 1998.
112. M. L. Hull, D. S. Charnock-Jones, C. L. K. Chan et al., "Antiangiogenic agents are effective inhibitors of endometriosis", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2889-2899, 2003.
113. A. G. Ricci, C. N. Olivares, M. A. Bilotas, G. F. Meresman, and R. I. Barañao, "Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis", Reproductive Sciences, vol. 18, no. 7, pp. 614-622, 2011.
114. A. Augoulea, G. Mastorakos, I. Lambrinoudaki, G. Christodoulakos, and G. Creatsas, "The role of the oxidative-stress in the endometriosis-related infertility", Gynecological Endocrinology, vol. 25, no. 2, pp. 75-81, 2009.
115. S. R. Pandi-Perumal, I. Trakht, V. Srinivasan et al., "Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways", Progress in Neurobiology, vol. 85, no. 3, pp. 335-353, 2008.
116. M. Güney, B. Oral, N. Karahan, and T. Mungan, "Regression of endometrial explants in a rat model of endometriosis treated with melatonin", Fertility and Sterility, vol. 89, no. 4, pp. 934-942, 2008.
117. O. Koc, B. Gunduz, A. Topcuoglu, G. Bugdayci, F. Yilmaz, and B. Duran, "Effects of pinealectomy and melatonin supplementation on endometrial explants in a rat model", European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 153, no. 1, pp. 72-76, 2010.
118. K. Chwalisz, M. C. Perez, D. De Manno, C. Winkel, G. Schubert, and W. Elger, "Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis", Endocrine Reviews, vol. 26, no. 3, pp. 423-438, 2005.
119. I. M. Spitz, "Clinical utility of progesterone receptor modulators and their effect on the endometrium", Current Opinion in Obstetrics and Gynecology, vol. 21, no. 4, pp. 318-324, 2009.
120. N. Chabbert-Buffet, A. Pintiaux, and P. Bouchard, "The immninent dawn of SPRMs in obstetrics and gynecology", Molecular and Cellular Endocrinology, vol. 358, no. 2, pp. 232-243, 2012.
121. J. Steinauer, E. A. Pritts, R. Jackson, and A. F. Jacoby, "Systematic review of mifepristone for the treatment of uterine leiomyomata", Obstetrics and Gynecology, vol. 103, no. 6, pp. 1331-1336, 2004.
122. F. M. Horne and D. I. Blithe, "Progesterone receptor modulators and the endometrium: changes and consequences", Human Reproduction Update, vol. 13, no. 6, pp. 567-580, 2007.
123. G. L. Mutter, C. Bergeron, L. Deligdisch et al., "The spectrum of endometrial pathology induced by progesterone receptor modulators", Modern Pathology, vol. 21, no. 5, pp. 591-598, 2008.
124. J. Jiang, R. Wu, Z. Wang, H. Sun, Z. Xu, and H. Xiu, "Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro", Fertility and Sterility, vol. 77, no. 5, pp. 995-1000, 2002.
125. L. Mei, J. Bao, L. Tang et al., "A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies", European Journal of Pharmaceutical Sciences, vol. 39, no. 5, pp. 421-427, 2010.
126. L. M. Kettel, A. A. Murphy, A. J. Morales, A. Ulmann, E. E. Baulieu, and S. S. C. Yen, "Treatment of endometriosis with the antiprogesterone mifepristone (RU486)", Fertility and Sterility, vol. 65, no. 1, pp. 23-28, 1996.
127. K. Chwalisz, K. Mattia-Goldberg, M. Lee, W. Elger, and A. Edmonds, "Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil", Fertility and Sterility, vol. 82, supplement 2, abstract O-207, pp. S83-S84, 2004.
128. B. J. Attardi, J. Burgenson, S. A. Hild, J. R. Reel, and R. P. Blye, "CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914", Molecular and Cellular Endocrinology, vol. 188, no. 1-2, pp. 111-123, 2002.
129. O. B. Ioffe, R. J. Zaino, and G. L. Mutter, "Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator", Modern Pathology, vol. 22, no. 3, pp. 450-459, 2009.
130. Y. Kawano, K. Nasu, H. Li et al., "Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target", Human Reproduction, vol. 26, no. 9, pp. 2486-2498, 2011.
131. Y. Lu, J. Nie, X. Liu, Y. Zheng, and S. W. Guo, "Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice", Human Reproduction, vol. 25, pp. 1014-1025, 2010.
132. M. L. Mmed, X. Liu, Y. Zhang, and S.-W. Guo, "Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats", Reproductive Sciences, vol. 19, no. 4, pp. 360-373, 2012.
133. X. Liu and S. W. Guo, "A pilot study on the off-label use of valproic acid to treat adenomyosis", Fertility and Sterility, vol. 135, pp. 88-93, 2007.
134. X. Liu, L. Yuan, and S. W. Guo, "Valproic acid as a therapy for adenomyosis: a comparative case series", Reproductive Sciences, vol. 17, no. 10, pp. 904-912, 2010.